GHAPPcast

Thank you to Madrigal for their support of this Medication Review Video Module.

In this medication review module, Michelle Barnett, PA-C, provides an in-depth overview of resmetirom, the first FDA-approved liver-directed thyroid hormone receptor beta (THR-β) agonist for adults with non-cirrhotic metabolic dysfunction–associated steatohepatitis (MASH) and moderate to advanced fibrosis (F2–F3). The discussion reviews MASH risk factors, resmetirom’s mechanism of action, dosing considerations, and key findings from the phase 3 MAESTRO-NASH trial, including improvements in liver histology and lipid parameters. Designed for APPs and clinicians, this concise review highlights how resmetirom fits into contemporary MASH management alongside lifestyle interventions such as diet and exercise.

In this expert-led podcast discussion on hepatitis B management, Elizabeth Goacher, PA-C, from Duke University Medical Center and Allison Moser, NP, from RUSH University Medical Center break down what’s new in chronic hepatitis B care and how evolving guidelines are shaping real-world clinical decision-making. Recorded onsite at GHAPP National, the conversation explores updated treatment thresholds from European Association for the Study of the Liver compared with American Association for the Study of Liver Diseases, including when to initiate antiviral therapy regardless of HBeAg status, the role of HBV DNA and ALT levels, and special considerations such as pregnancy, renal and bone health, adherence, and HIV co-infection. The episode also highlights practical antiviral selection, patient-centered counseling, risks of treatment interruption, and emerging therapies aimed at functional cure. This discussion offers timely, practice-focused insights for APPs and clinicians caring for patients with hepatitis B.

This in-depth conversation explores how advanced practice providers navigate some of the most challenging discussions in the care of patients living with chronic hepatitis B. Drawing from years of real-world hepatology and transplant experience, Jennifer Geremia, PA-C, and Andrea Keller, PA, discuss culturally sensitive communication, addressing stigma, improving health literacy, and building trust with patients and families affected by hepatitis B. The discussion highlights practical strategies for long-term disease management, medication adherence, family screening and vaccination, perinatal transmission counseling, and the importance of regular monitoring to prevent cirrhosis, hepatocellular carcinoma, and end-stage liver disease. The speakers also address common misconceptions, language barriers, and shared decision-making, offering actionable insights for APPs and clinicians caring for diverse hepatitis B populations.

#Hepatology #LiverDisease #ChronicHepatitisB #AdvancedPracticeProviders #GHAPP #TransplantHepatology #PatientCommunication #CulturalCompetency #HealthLiteracy #LiverCare #ChronicDiseaseManagement

In this expert-led podcast discussion, Patrick Horne and HoChong Gilles explore the complex management of comorbidities in patients with chronic viral hepatitis, with a focus on hepatitis B, hepatitis C, and HIV co-infection. The conversation highlights practical strategies for treatment sequencing, preventing hepatitis B reactivation during DAA therapy, managing drug–drug interactions, and optimizing long-term liver and systemic outcomes. The episode also examines the growing impact of metabolic dysfunction–associated steatotic liver disease (MASLD/MASH) on fibrosis progression and hepatocellular carcinoma (HCC) risk, along with current surveillance approaches including ultrasound and AFP. Additional insights address renal and bone health considerations with long-term hepatitis B antiviral therapy and the importance of multidisciplinary, whole-patient care when managing cardiovascular, metabolic, and renal co-morbidities in this high-risk population. Visit the GHAPP Digital Hub, Hep B Health Hub or GHAPP ACE app for more educational content.

Thank you to Madrigal for your support on this FAQ Video Module.

In this short FAQ video module, Patrick Horne, President of GHAPP and a nurse practitioner at the University of Florida, discusses the critical role of noninvasive tests (NITs) in risk stratification and patient selection for patients with metabolic dysfunction–associated steatohepatitis (MASH). He explains how serum biomarkers and imaging help establish baseline fibrosis, clarify disease severity, and guide clinical decision-making in a condition with variable and non-linear progression. This overview emphasizes the importance of integrating NITs with a thorough patient history and physical exam to better understand fibrosis stage and optimize patient evaluation.

Visit the GHAPP Digital Hub or GHAPP ACE 2.0 app for more gastroenterology and hepatology education.

Thank you to Madrigal for your support on this Journal Club Review video module.

This journal club review explores the 2025 focused recommendations for the management of metabolic dysfunction–associated steatohepatitis (MASH) developed by advanced practice providers (APPs) across the United States and published in the Journal of Clinical Gastroenterology. Brian Lam, PA-C, reviews the evolving role of APPs in MASH care, key epidemiology insights, risk stratification using non-invasive tests, and practical guidance on identifying and treating at-risk patients with F2–F3 fibrosis. The discussion highlights real-world use of ELF, FibroScan, and FIB-4, an overview of resmetirom therapy, monitoring strategies, and a look ahead at emerging therapies shaping the future of MASH management.

Thank you to Madrigal for your support of this Medication Review Video Module.

Discover how Resmetirom is reshaping the treatment landscape for metabolic dysfunction–associated steatohepatitis (MASH) in this expert-led medication review with HoChong Gilles, DNP. This short medication review breaks down the therapy’s mechanism of action, pivotal MAESTRO-NASH trial data, fibrosis and steatohepatitis endpoints, ideal patient selection (F2–F3 disease), and key safety considerations. Learn how this first-in-class THR-β agonist delivers meaningful improvements in fibrosis and steatohepatitis without worsening disease, and why 2024 marked a turning point in MASH care. Perfect for APPs and clinicians looking to stay ahead in the rapidly evolving world of liver disease management.

Thank you to Madrigal for your support on this FAQ Video Module.

In this episode, Christina Hanson, NP, breaks down the key functional and prognostic differences between fibrosis stage F3 and F4, explaining how liver architecture, portal hypertension, and risk of decompensation shape patient outcomes. Learn how staging impacts mortality risk in MASLD/MASH, why accurate identification of advanced fibrosis is critical, and how management strategies differ for patients with severe fibrosis versus cirrhosis. Christina reviews how clinicians can intervene early, slow progression, and monitor for complications such as variceal bleeding, ascites, and hepatic encephalopathy, while emphasizing the importance of addressing underlying liver disease to improve long-term survival.

#Fibrosis #LiverDisease #MASLD #MASH #Cirrhosis #F3Fibrosis #F4Fibrosis #LiverHealth #Hepatology #AdvancedFibrosis #LiverCare #NAFLD #NASH #PortalHypertension #LiverTransplant

In this final episode of our RhAPP, MAPP, GHAPP, and SDPA crosscast series, expert APPs from dermatology, gastroenterology, rheumatology, and obesity medicine break down the most important conversation of all—how to talk to patients about obesity and immune-mediated inflammatory diseases (IMIDs). This discussion focuses on real-world communication strategies, reducing stigma, motivational interviewing, shared decision-making, and setting small, achievable goals that improve outcomes. Learn how to approach sensitive weight-related conversations with empathy, build trust, and empower patients to better manage obesity and chronic inflammation in everyday practice.

In this cross-specialty episode of our RhAPP, GHAPP, MAPP and SDPA collaborative series, leading APPs from dermatology, gastroenterology, rheumatology, and metabolic medicine break down real-world strategies to improve outcomes for patients living with both obesity and immune-mediated inflammatory diseases (IMIDs). Building on earlier discussions about epidemiology and pathophysiology, this conversation focuses on practical, clinic-ready approaches—from shared decision-making and compassionate patient communication to interdisciplinary coordination, GLP-1 utilization, and lifestyle guidance. Learn how APPs across specialties are uniting to reduce systemic inflammation, personalize care, and translate education into meaningful action for patients with obesity and IMIDs.